Fact-checked by the Peptide Authority Editorial Board · Last reviewed: 2026-02-01
What Is Ghrelin? Benefits, Research & Safety
The 'hunger hormone' that stimulates appetite and growth hormone release, with important roles in metabolism and energy balance.
Also known as:
The Hunger Hormone
Lenomorelin
Growth Hormone Secretagogue
Educational Content Only: This page provides research-based information for educational purposes. Ghrelin is not an approved medicine. This is not medical advice. Always consult a qualified healthcare professional.
Quick Facts
Category
Fat Loss & Metabolic
Half-Life
Very short; approximately 10-30 minutes for acyl-ghrelin
UK Status
Not approved for therapeutic use. Research compound.
EU Status
Not approved. Research only.
Overview
Ghrelin is a 28-amino acid peptide hormone primarily produced by specialised cells in the stomach lining. It is the only known hormone that stimulates appetite, earning it the nickname "hunger hormone." Ghrelin levels rise before meals and fall after eating, playing a key role in meal initiation and energy homeostasis.
Beyond appetite stimulation, ghrelin has multiple biological effects: it stimulates growth hormone release from the pituitary, affects glucose and lipid metabolism, modulates gastrointestinal function, and influences cardiovascular and immune systems.
Ghrelin was discovered in 1999 as the endogenous ligand for the growth hormone secretagogue receptor (GHSR, now called the ghrelin receptor). This connected the peptide to both appetite regulation and the growth hormone axis.
The understanding that ghrelin drives hunger has made it an attractive target for obesity treatment—blocking ghrelin might reduce appetite and promote weight loss. Conversely, ghrelin agonists could help conditions characterised by poor appetite and wasting (cachexia, anorexia).
Ghrelin mimetics are in clinical development for various conditions, though none have achieved widespread approval for appetite modulation.
Discovery & History
Ghrelin was discovered in 1999 by Masayasu Kojima and colleagues in Japan. They identified it as the endogenous ligand for the growth hormone secretagogue receptor (GHS-R), which had been known since the development of synthetic growth hormone secretagogues.
The name "ghrelin" derives from "ghre," a Proto-Indo-European root for "grow," reflecting its growth hormone-releasing activity. The discovery explained how synthetic GH secretagogues like GHRP-6 worked—they mimicked an endogenous signal.
The surprising finding was that ghrelin was primarily produced in the stomach, not the brain. This established a gut-brain signaling axis connecting nutritional status to hypothalamic appetite centers.
Research quickly revealed ghrelin's potent orexigenic (appetite-stimulating) effects. Ghrelin levels rise before meals (preprandial) and fall after eating, acting as a meal initiation signal. This positioned ghrelin as a potential target for obesity treatment.
Studies in conditions like anorexia nervosa, cachexia, and post-surgical patients have explored both the pathophysiology of ghrelin dysregulation and therapeutic potential of ghrelin or ghrelin agonists.
The ghrelin-growth hormone connection has also led to interest in ghrelin for age-related conditions, though the complexity of ghrelin biology has made therapeutic development challenging.
Mechanism of Action
Ghrelin acts primarily through the growth hormone secretagogue receptor (GHSR-1a):
**GHSR Activation in Hypothalamus**
Central effects on appetite:
- Activates NPY/AgRP neurons (appetite-stimulating)
- Inhibits POMC/CART neurons (appetite-suppressing)
- Results in increased hunger and food intake
- Affects food reward and motivation
**Pituitary Effects**
Growth hormone secretagogue activity:
- Stimulates GH release from somatotrophs
- Works synergistically with GHRH
- Contributes to pulsatile GH secretion
**Peripheral Effects**
Direct effects in various tissues:
- Stomach: Regulates gastric motility and acid secretion
- Adipose tissue: Effects on lipid metabolism
- Liver: Modulates glucose metabolism
- Heart: Potential cardioprotective effects
**Unique Modification**
Ghrelin requires acylation (addition of octanoyl group) for receptor activation:
- Acyl-ghrelin is the active form
- Des-acyl ghrelin has different (often opposing) effects
- Ghrelin O-acyltransferase (GOAT) enzyme is required
- This has therapeutic implications
**Integration with Other Signals**
Ghrelin interacts with leptin and insulin:
- Ghrelin and leptin have opposing effects on appetite
- Insulin suppresses ghrelin secretion
- Complex interplay determines energy balance
[Molecular Structure Diagram Placeholder]
Researched Benefits
Based on preclinical and clinical research findings:
- 1Potent appetite stimulation
- 2Growth hormone release
- 3Potential treatment for cachexia and wasting
- 4Gastrointestinal motility effects
- 5Possible cardioprotective properties
- 6Research target for obesity (antagonists) and wasting (agonists)
Theoretical Dosing & Protocols
⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.
| Theoretical Dosage | Variable in research; typically microgram amounts IV |
| Frequency | Variable depending on research application |
| Duration | Variable |
| Notes | Ghrelin itself is not used therapeutically due to complexity of administration and effects. Ghrelin receptor agonists are in development for cachexia and other conditions. Research use only. |
Administration Routes
Routes studied in research settings (educational only):
- Intravenous (research)
- Subcutaneous (some studies)
- Oral ghrelin agonists in development
| Half-Life | Stability |
|---|---|
| Very short; approximately 10-30 minutes for acyl-ghrelin | Acyl-ghrelin subject to deacylation; requires careful handling |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Increased appetite and food intake
- Effects on glucose metabolism
- GI effects
- Flushing
Rare Risks & Concerns
- Unknown long-term effects of chronic elevation
- Potential metabolic consequences
- Effects on growth hormone axis
Contraindications
- Research compound only—not used therapeutically
- Obesity would be a relative contraindication for agonists
UK & EU Regulatory Context
🇬🇧 United Kingdom
Not approved for therapeutic use. Research compound.
🇪🇺 European Union
Not approved. Research only.
Ghrelin itself is not used therapeutically. Ghrelin receptor agonists (like anamorelin) have been studied for cachexia and are approved in some countries (Japan). The ghrelin system remains an active therapeutic target.
Clinical Studies Summary
Ghrelin in Cancer Cachexia
Clinical trials of ghrelin and ghrelin agonists for cancer-related wasting.
Oncology and cachexia journalsView on PubMed
Ghrelin and Appetite Regulation
Research characterising ghrelin's role in hunger and meal initiation.
Endocrinology and metabolism journalsView on PubMed
Looking for Ghrelin?
Source research-grade Ghrelin from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Related Peptides
GLP-1
A naturally occurring gut hormone that regulates glucose metabolism and appetite, serving as the basis for major obesity and diabetes medications.
Learn moreIpamorelin
A selective growth hormone-releasing peptide known for its favourable side effect profile, stimulating GH release without significantly affecting cortisol or prolactin.
Learn moreGHRP-6
The first clinically evaluated growth hormone-releasing peptide, notable for its potent GH release and pronounced appetite-stimulating effects.
Learn moreGLP-1
A natural incretin hormone that regulates blood glucose and appetite, the basis for revolutionary diabetes and obesity medications.
Learn moreAmylin
A pancreatic hormone co-secreted with insulin that regulates glucose and appetite, the basis for the diabetes drug pramlintide.
Learn moreLeptin
A hormone produced by fat cells that regulates appetite, energy expenditure, and body weight.
Learn more